home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

BioXcel Therapeutics, Inc. - Common Stock (NQ:BTAI)

1.890 +0.050 (+2.72%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioXcel Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies

February 14, 2024

From FN Media Group LLC

Via GlobeNewswire

Why BioXcel Therapeutics Shares Are Falling Today ↗

February 09, 2024

BioXcel Therapeutics sees a dip in shares as it launches a $60 million public offering to fund clinical trials and corporate needs.

Via Benzinga

Expert Ratings for BioXcel Therapeutics ↗

November 15, 2023

Via Benzinga

Recap: BioXcel Therapeutics Q3 Earnings ↗

November 14, 2023

Via Benzinga

Earnings Outlook For BioXcel Therapeutics ↗

November 13, 2023

Via Benzinga

Leading The Charge: Tonix Pharmaceuticals And The Future Of CNS Therapeutics

February 13, 2024

Via Get News

Why BioXcel Therapeutics Shares Are Rising Tuesday ↗

February 13, 2024

BioXcel Therapeutics shares surge 25.1% as the company terminates its proposed public offering and shifts focus to upcoming FDA meeting and Phase 3 trial.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

February 13, 2024

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

February 12, 2024

Via Benzinga

BIOXCEL ALERT: Bragar Eagel & Squire, P.C. is Investigating BioXcel Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

February 09, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

February 09, 2024

Via Benzinga

Why Take-Two Interactive Software Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

February 09, 2024

Shares of Take-Two Interactive Software, Inc. (NASDAQ: TTWO) fell sharply during Friday’s session following third-quarter results.

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

February 09, 2024

Via Benzinga

Why Is CleanSpark (CLSK) Stock Up 27% Today? ↗

February 09, 2024

CleanSpark stock is rising higher on Friday as investors in CLSK shares celebrate the company's positive Q1 earnings report.

Via InvestorPlace

S&P 500 Tops 5,000; PepsiCo Posts Upbeat Earnings ↗

February 09, 2024

U.S. stocks traded mixed this morning, with the S&P 500 topping the 5,000 mark on Friday. Following the market opening Friday, the Dow traded down 0.05% to 38,706.33 while the NASDAQ rose 0.32% to...

Via Benzinga

Topics Stocks

Why Is BioXcel Therapeutics (BTAI) Stock Down 26% Today? ↗

February 09, 2024

BioXcel Therapeutics stock is falling on Friday after the company announced plans for a proposed public offering of BTAI shares.

Via InvestorPlace

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

February 09, 2024

Via Benzinga

Why Cloudflare Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket ↗

February 09, 2024

Shares of Cloudflare, Inc. (NYSE: NET) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter financial results and

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

February 09, 2024

It's time to start the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!

Via InvestorPlace

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

February 08, 2024

Via Benzinga

AI-Focused Drug Discovery Stocks Index Up 26% In December ↗

December 29, 2023

With the promise of lower costs and shorter development timelines, AI-enabled drug discovery holds massive potential to increase the accessibility of drugs and to treat presently incurable conditions.

Via Talk Markets

AI-Focused Drug Discovery Stocks Index Up 10.6% Last Week ↗

December 17, 2023

A new study concludes that the AI method of drug discovery is up to 250 times more efficient than the traditional method.

Via Talk Markets

Topics Artificial Intelligence

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Long Term Investor Notice: Investigation of Potential Wrongdoing ↗

December 08, 2023

San Diego, CA -- (SBWIRE) -- 12/08/2023 -- An investigation on behalf of current long-term investors in shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI) concerning potential breaches of fiduciary...

Via SBWire

Micro/Small Cap Companies Using AI In Drug Discovery Up 35% In November ↗

December 06, 2023

The AI method is up to 250 times more efficient than the traditional method of drug discovery. reducing timelines for drug discovery, increasing accuracy of efficacy and safety predictions.

Via Talk Markets

Topics Artificial Intelligence

Unlocking AI investment opportunities in healthcare

November 16, 2023

AI is revolutionizing healthcare by improving diagnosis and accelerating drug discovery. An often-overlooked sector with a wealth of AI opportunities.

Via MarketBeat

Topics Artificial Intelligence ETFs

Why Is Dementia Focused BioXcel Therapeutics Stock Trading Lower Today? ↗

November 14, 2023

BioXcel Therapeutics Inc (NASDAQ: BTAI) announced alignment with the FDA's recommendation for a Phase 3 trial in the TRANQUILITY program of BXCL501 for acute treatment of agitation associated

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 14, 2023

Via Benzinga

Why Beyond Air Shares Are Trading Lower By Around 37%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

November 14, 2023

Shares of Beyond Air, Inc. (NASDAQ: XAIR) dipped during Tuesday’s session following weak quarterly results.

Via Benzinga

BioXcel Therapeutics Reveals Survival Data From Prostate Cancer Combo Therapy Trial ↗

November 08, 2023

BioXcel Therapeutics Inc (NASDAQ: BTAI) announced overall survival (OS) data from its Phase 2 trial of BXCL701 in combination with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) in patients wi

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

October 30, 2023

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com